Cargando…

Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study

BACKGROUND: After primary vaccination schemes with rAd26-rAd5 (Sputnik V), ChAdOx1 nCoV-19, BBIBP-CorV or heterologous combinations, the effectiveness of homologous or heterologous boosters (Sputnik V, ChAdOx, Pfizer-BioNTech, Moderna) against SARS-CoV-2 infections, hospitalisations and deaths has b...

Descripción completa

Detalles Bibliográficos
Autores principales:	González, Soledad, Olszevicki, Santiago, Gaiano, Alejandra, Salazar, Martín, Regairaz, Lorena, Varela Baino, Ana Nina, Bartel, Erika, Varela, Teresa, González Martínez, Veronica V., Pesci, Santiago, Marín, Lupe, Irassar, Juan Ignacio, Ceriani, Leticia, Garcia, Enio, Kreplak, Nicolás, Estenssoro, Elisa, Marsico, Franco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558771/ https://www.ncbi.nlm.nih.gov/pubmed/37808936 http://dx.doi.org/10.1016/j.lana.2023.100607

Ejemplares similares

Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study
por: González, Soledad, et al.
Publicado: (2022)

Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina
por: González, Soledad, et al.
Publicado: (2021)

rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1
por: Montefiori, DC, et al.
Publicado: (2012)

Myocarditis following rAd26 and rAd5 vector‐based COVID‐19 vaccine: correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Myocarditis following rAd26 and rAd5 vector‐based COVID‐19 vaccine: case report
por: Naghashzadeh, Farah, et al.
Publicado: (2022)

Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study
por: Rearte, Analía, et al.
Publicado: (2022)

Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein
por: Pouriayevali, Mohammad Hassan, et al.
Publicado: (2022)

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)
por: Crank, Michelle C., et al.
Publicado: (2016)

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
por: Logunov, Denis Y, et al.
Publicado: (2021)

Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273
por: Pascuale, Carla A., et al.
Publicado: (2022)

Corrigendum to “Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein” [Vaccine 40(20) (2022) 2856–2868]
por: Pouriayevali, Mohammad Hassan, et al.
Publicado: (2022)

rAd5 prime/NYVAC-B boost regimen is superior to NYVAC-B prime/rAd5 boost regimen for both response rates and magnitude of CD4 and CD8 T-cell responses
por: Bart, P, et al.
Publicado: (2012)

Biochemical and histopathological evaluation of ChAdOx1-S and BBIBP-CorV vaccination in normal and streptozotocin-induced diabetic Wistar rats
por: Teymoorzadeh, Mahsa, et al.
Publicado: (2023)

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
por: Logunov, Denis Y, et al.
Publicado: (2020)

Boosting BCG with proteins or rAd5 does not enhance protection against tuberculosis in rhesus macaques
por: Darrah, Patricia A., et al.
Publicado: (2019)

Therapeutic effects of lenvatinib in combination with rAd-p53 for the treatment of non-small cell lung cancer
por: Yu, Renzhi, et al.
Publicado: (2018)

BBIBP-CorV: Hepatitis: case report
Publicado: (2022)

Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals
por: Eybpoosh, Sana, et al.
Publicado: (2023)

Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study
por: Tukhvatulin, Amir I., et al.
Publicado: (2023)

BBIBP-CorV: Anterior uveitis: case report
Publicado: (2022)

Bbibp-corv: Acute ischaemic stroke: case report
Publicado: (2022)

Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial
por: Li, Yi, et al.
Publicado: (2014)

Adverse events and SARS-CoV-2 antibody responses after immunization with Sputnik V, ChAdOx1-S, and BBIBP-CorV vaccines in people with HIV
por: Mauas, Romina, et al.
Publicado: (2023)

Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
por: Jeewandara, Chandima, et al.
Publicado: (2022)

BBIBP-CorV: Steven-Johnson syndrome : case report
Publicado: (2022)

BBIBP-CorV: Acute disseminated encephalomyelitis: case report
Publicado: (2022)

BBIBP-CorV: Stevens-Johnson syndrome: case report
Publicado: (2022)

BBIBP-CorV: Stevens-Johnson-syndrome: case report
Publicado: (2022)

Synergism therapeutic and immunoregulatory effects of Albendazole + rAd-mIL-28B against Echinococcosis in experiment-infected mice with protoscoleces
por: Zhang, Yan, et al.
Publicado: (2021)

Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people
por: Rouco, Santiago Oviedo, et al.
Publicado: (2022)

Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine: A comparative study among healthcare professionals of Nepal
por: Rayamajhi, Sushil, et al.
Publicado: (2022)

The Impact of Adding Digital Breast Tomosynthesis to BI-RADS Categorization of Mammographically Equivocal Breast Lesions
por: Hassan, Rania Mostafa, et al.
Publicado: (2023)

Sinopharm’s BBIBP-CorV Vaccine and ChAdOx1 nCoV-19 Vaccine Are Associated with a Comparable Immune Response against SARS-CoV-2
por: Abdelhafiz, Ahmed Samir, et al.
Publicado: (2022)

BBIBP-CorV/tozinameran: Subacute thyroiditis: 2 case reports
Publicado: (2022)

BBIBP-CorV: Adult multisystem inflammatory syndrome: case report
Publicado: (2021)

BBIBP-CorV: Eye disorders and hypertension: 7 case reports
Publicado: (2021)

Heterologous Prime-Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular Immune Responses to HIV Proteins Than Homologous Regimens
por: Ratto-Kim, Silvia, et al.
Publicado: (2012)

P18-06. Increased HIV-specific immunity in HIV-infected individuals vaccinated with a DNA prime, rAd5 boost regimen
por: Casazza, JP, et al.
Publicado: (2009)

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials
por: Huang, Yunda, et al.
Publicado: (2015)

R.F. cavity for AD machine
por: Laurent Guiraud
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_gqgicgqbl640lfi606evq53fvc